期刊文献+

伊马替尼治疗慢性粒细胞白血病急变期的疗效观察 被引量:3

下载PDF
导出
摘要 目的探讨伊马替尼治疗慢性粒细胞白血病急变期的疗效。方法 2005年2月至2010年2月收治慢性粒细胞白血病急变期患者148例,依据治疗方法不同分为伊马替尼组78例,常规治疗组70例,观察两组临床疗效。结果伊马替尼组总有效率51.28%,常规治疗组总有效率12.85%,两组总有效率比较P<0.01有显著差异性。结论应用伊马替尼治疗慢性粒细胞白血病急变期能够取得近期良好的临床效果用药方便,毒性反应轻微,明显延长患者生命,改善患者生活质量。
出处 《中国实用医药》 2012年第15期162-163,共2页 China Practical Medicine
  • 相关文献

参考文献3

二级参考文献5

  • 1[1]Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR - ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with Philadephia chromosome. N Engl J Med, 2001,344:1038~ 1042.
  • 2[2]Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase Ⅱ study. Blood, 2002,99:3530~3539.
  • 3[3]Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI- 571 cancer therapy caused by BCR- ABL gene mutation oramplification. Science, 2001,293:876~880.
  • 4SAVAGE D G,ANTMAN K H.Imatinib mesylate-a new oral targeted therapy[J].N Engl J Med,2002,34:683-693.
  • 5OHYASHIKI K,OHYASHIKI J H,IWAMA H,et al.Telomerase activity and cytogenetic changes in chronic myeloid leukemia with disease progression[J].Leukemia,1997,11:190-194.

共引文献16

同被引文献62

  • 1苏琼,辛继胜,吴斌,石建荣,陆井之,欧剑峰.慢性粒细胞白血病急淋变2例[J].中国临床实用医学,2007,1(1). 被引量:1
  • 2骆宏,谢斌.自我管理模式及其在精神卫生服务中的应用[J].上海精神医学,2004,16(2):117-119. 被引量:103
  • 3陈秋生,李军民,孙慧平,沈志祥.慢性髓细胞白血病向T淋巴细胞淋巴瘤/白血病急变一例和文献复习[J].上海医学,2007,30(3):171-175. 被引量:8
  • 4American Cancer Society. Cancer facts and gures 2010 [ M ]. Atlanta: American Cancer Society,2010:55.
  • 5Au WY, Caguioa PB, Chuah C ,et al. Chronic myeloid leukemia in Asia[J]. Int J Hematol, 2009,89(1) :14-23.
  • 6Baccarani M, Dreyling M, ESMO Guidelines Working Group. Chronic myeloid leukaemia:ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up [ J ]. Ann Oncol, 2010, 21 ( Suppl 5 ) :v165-167.
  • 7Phillips KM, Pinilla-Ibarz J, Sotomayor E, et al. Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors : a controlled comparison [ J 1. Support Care Cancer, 2013,21 (4) :1097-1103.
  • 8Efficace F, Kemmler G, Vignetti M, et al. Health-related quality of life assessment and reported outcomes in leukaemia randomised controlled trials-a systematic review to evaluate the added value in supporting clinical decision making[ J]. Eur J Cancer,2008,44 ( 11 ) : 1497-1506.
  • 9Efficace F, Cocks K, Breccia M, et al. Time for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: inclusion of quality of life and other patient-reported outcomes[J]. Crit Rev Oncol Hematol, 2012,81(2) :123-135.
  • 10Efficace F, Baccarani M, Breccia M, et al. Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib [ J ]. Leukemia, 2013,27(7) :1511-1519.

引证文献3

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部